Nautilus Biotechnology (NASDAQ:NAUT) Research Coverage Started at Leerink Partners
by Jessica Moore · The Cerbat GemLeerink Partners started coverage on shares of Nautilus Biotechnology (NASDAQ:NAUT – Free Report) in a research note released on Wednesday, MarketBeat.com reports. The brokerage issued an outperform rating and a $4.00 price target on the stock.
Separately, Weiss Ratings downgraded Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Nautilus Biotechnology currently has a consensus rating of “Hold” and a consensus price target of $4.00.
Check Out Our Latest Research Report on NAUT
Nautilus Biotechnology Stock Performance
Shares of NAUT stock opened at $1.02 on Wednesday. Nautilus Biotechnology has a 52-week low of $0.68 and a 52-week high of $4.31. The company has a 50-day simple moving average of $1.20 and a two-hundred day simple moving average of $2.16. The company has a market capitalization of $129.79 million, a price-to-earnings ratio of -2.27 and a beta of 0.87.
Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) last posted its earnings results on Monday, July 27th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.03. The firm had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.10 million.
Institutional Trading of Nautilus Biotechnology
A number of large investors have recently added to or reduced their stakes in NAUT. CTC Alternative Strategies Ltd. purchased a new position in Nautilus Biotechnology in the first quarter valued at about $48,000. TD Waterhouse Canada Inc. increased its stake in shares of Nautilus Biotechnology by 1,500.0% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 16,000 shares of the company’s stock worth $29,000 after purchasing an additional 15,000 shares during the last quarter. Garde Capital Inc. bought a new stake in shares of Nautilus Biotechnology in the 4th quarter worth approximately $35,000. Hudson Bay Capital Management LP bought a new stake in shares of Nautilus Biotechnology in the 4th quarter worth approximately $37,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Nautilus Biotechnology in the 1st quarter worth approximately $75,000. Hedge funds and other institutional investors own 50.71% of the company’s stock.
Nautilus Biotechnology Company Profile
Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.
Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.